Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18682845 | 0.83 | OPRM1 (0.49) | OPRM1SLC6A3SLC6A4SLC6A2KDM1A | |
| SCHEMBL13698123 | 0.81 | OPRM1 (0.42) | OPRM1SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL20459104 | 0.81 | OPRM1 (0.42) | OPRM1SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL4194504 | 0.81 | OPRM1 (0.42) | OPRM1SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL13698121 | 0.81 | OPRM1 (0.42) | OPRM1SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL4185836 | 0.81 | OPRM1 (0.42) | OPRM1SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL17303200 | 0.81 | OPRM1 (0.42) | OPRM1SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL11047193 | 0.73 | OPRM1 (0.59) | OPRM1SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL13253935 | 0.73 | OPRM1 (0.59) | OPRM1SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL29539848 | 0.72 | CCR1 (0.42) | OPRM1SLC6A3SLC6A4SLC6A2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | OPRM1 258/4885SLC6A3 92/4885SLC6A4 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.